June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Reduced tear Thrombospondin-1/Matrix Metalloproteinase 9 ratio can aid diagnosing Sjögren’s syndrome related ocular surface inflammation.
Author Affiliations & Notes
  • Sharmila Masli
    Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States
  • Esen K Akpek
    Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Sharmila Masli Boston University School of Medicine, 701586-191100PL01, Code P (Patent); Esen Akpek Adelphi Values, Code C (Consultant/Contractor), Dompe, Code C (Consultant/Contractor), Epitech, Code C (Consultant/Contractor), FirstString Medical Research, Code C (Consultant/Contractor), Novalique, Code C (Consultant/Contractor), Regneron Healthcare Solutions Inc., Code C (Consultant/Contractor), W.L. Gore & Associates Inc., Code F (Financial Support), Ocular Therapeutix, Code F (Financial Support)
  • Footnotes
    Support  Sjögren's Foundation Research Award
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1099. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sharmila Masli, Esen K Akpek; Reduced tear Thrombospondin-1/Matrix Metalloproteinase 9 ratio can aid diagnosing Sjögren’s syndrome related ocular surface inflammation.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1099.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diagnosing Sjögren’s syndrome (SS) underlying ocular surface inflammation is critical due to systemic co-morbidities and complications, however, currently not feasible using available tests. We tested the hypothesis that reduced tear levels of immunoregulatory Thrombospondin (TSP)-1, which also inhibits Matrix Metalloproteinase (MMP)-9, would reflect SS pathology. We performed a prospective observational case-control study to learn about changes in tear TSP-1 and MMP-9 levels in patients with ocular surface inflammation associated with SS vs. Non-SS causes.

Methods : Total 61 participants (healthy or with clinically significant ocular surface inflammation with or without a definitive diagnosis of SS) were included. In addition to tear sampling, clinical evaluations included non-invasive tear break-up time (BUT), tear osmolarity, Schirmer’s test without anesthesia, and ocular surface staining (lissamine green for conjunctiva and fluorescein for cornea). Tear TSP-1 and MMP-9 levels were determined using custom magnetic bead-based multi-plex assay (MilliporeSigma, Burlington, MA, USA) in a masked fashion. Statistical analysis procedures included regression analysis and Fisher’s Exact test.

Results : Average tear TSP-1 and MMP-9 levels in healthy participants (control group) were 322 and 12.2 ng/ml respectively. Significantly higher proportion of participants with SS-associated ocular surface inflammation than non-SS causes had tear TSP-1 levels below the control group average (55% vs. 29%, OR=3, 95%CI=1.64 to 5.35, p<0.05) and tear MMP-9 levels above the control group average (65% vs. 24%, OR=5.8, 95%CI=4.46 to 19.81, p<0.05). Tear TSP-1/MMP-9 ratio was significantly reduced when ocular surface inflammation was associated with SS as against non-SS causes (B= -2.36, 95% CI= -3.94 to -.0.79, p<0.05), regardless of tear MMP-9 levels. Patients with higher ratio were 72% less likely to have SS (OR=0.28, 95% CI= 0.1 to 0.75, p<0.05) and this ratio showed significant correlations with conjunctival and corneal staining scores (R= -0.3 and R= -0.29, respectively p<0.05).

Conclusions : Our results are consistent with our hypothesis and indicate that reduced tear TSP-1 level is associated with SS pathology underlying ocular surface inflammation. Thus tear TSP-1/MMP-9 ratio can be a useful test that aids in diagnosis of SS-associated ocular surface inflammation.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×